New Talk: Alleviate Crucial Challenges in Scaling Up Gene Therapy Manufacturing
Emily Moran, VP of Vector Manufacturing, Center for Breakthrough Medicines
As vector-delivered advanced therapies are brought to market, lack of capacity has posed issues for manufacturing, subsequently delaying time to market for therapies that could save patient lives. Early process optimization sets the stage for clinical and commercial manufacturing and plays a foundational role in decreasing time to market and lowering the costs of AAV production. This video details how designing modular, BLA/MAA-ready cleanrooms with configurability for unique process needs leads to rapid and high-yielding vector production.
Watch the full talk below.
In need of immediate assistance with your advanced therapy manufacturing? Contact us here or simply call to speak with a CBM expert: 866-274-4009.